You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Monodispersed magnetic nanoparticles for improved diagnostic imaging. Phase II: S

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic cancer (PC) is the fourth leading cause of death from cancer in the US. Treatment options for this disease are extremely limited and prognosis is poor. At present, less than 6% of PC patients are alive afterfive years with an average survival time following diagnosis of 4-6 months, which is among the lowest for all cancers. It is clear that new thera ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: APT THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds of patients with metastatic bone cancer experience severe pain which is usually described as dull in character, constant in presentation, and gradually increasing in intensity with time. Bone cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

    SBC: REGENX BIOSCIENCES, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated efficacy of monthly intravitreal injections of the monoclonal bevacizumab in treating wet AMD that is accompanied by a high cost ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Using Text Messaging for Developmental Screening in Young Children

    SBC: Voxiva, Inc            Topic: NICHD

    DESCRIPTION (provided by applicant): Early identification of developmental problems and delays means that interventions can begin sooner and are more effective and less resource-intensive than later interventions, after a problem has festered and worsened.Despite these benefits, statistics indicate that few infants and toddlers actually receive such screenings (AAP 2006). The goal of this Phase I ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Mesodissection Device Phase II

    SBC: MEDSOCKET OF MISSOURI, INC.            Topic: NLM

    DESCRIPTION (provided by applicant): Physicians, no matter how well prepared, generate an average of two clinical questions per every three patient encounters. In 2009, the 1.3 billion visits to physicians' offices, hospital outpatient departments, and hospital emergency departments produced roughly 867 million questions. Answers to such questions likely exist, typically spread among several ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Hiltonol provides potent neuroprotection from ischemic brain injury in stroke.

    SBC: Oncovir            Topic: NINDS

    DESCRIPTION (provided by applicant): Brain ischemia is a leading cause of morbidity and mortality in the United States. We seek to develop therapeutics to reduce the extent of damage and functional impairment resulting from ischemic injury to the brain, anarea of significant unmet medical need. We have shown that ligand activation of the Toll-like receptor (TLR) family of pattern recognition recep ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Developing an Improved Electrocompetent E. coli Host

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCATS

    DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Developing and Scaling an interactive text messaging tool to help pregnantsmoker

    SBC: Voxiva, Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): There is no more important target audience for smoking cessation efforts than pregnant women. The goal of this Fast Track project is to establish the scientific and technical feasibility of using an interactive text- and web-based application to support smoking cessation among pregnant women. This project aims to develop the first-ever text message based smokin ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government